2 terminated, 2 withdrawn, 1 completed. 5 Phase 2, 4 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Terminated 2, Withdrawn 2, Completed 1 |
| Phase 1 | 4 | Withdrawn 2, Completed 1, Terminated 1 |
Follow CD22 Positive: new trials by email Literature Review of CD22 Positive trials Research Report on CD22 Positive
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Inotuzumab Ozogamicin and Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia Inotuzumab Ozogamicin, Quality-of-Life Assessment, Vincristine Sulfate Liposome - Allogeneic Hematopoietic Stem Cell Transplantation Recipient, Blasts 5 Percent or More of Bone Marrow Nucleated Cells | Phase 1 / Phase 2 | Withdrawn | Roswell Park Cancer Institute | 2021-01-21 | 2022-01-28 | |
| Modified Immune Cells (CD19-CD22 CAR T Cells) in Treating Patients With Recurrent or Refractory CD19 Positive, CD22 Positive Leukemia or Lymphoma Autologous CD19/CD22 Chimeric Antigen Receptor T-cells, Cyclophosphamide, Fludarabine - CD19 Positive, CD22 Positive | Phase 1 / Phase 2 | Withdrawn | M.D. Anderson Cancer Center | 2019-05-15 | 2023-08-21 | |
| ADCT-602 in Treating Patients With Recurrent or Refractory B-cell Acute Lymphoblastic Leukemia ADCT-602 - Blasts 5 Percent or More of Bone Marrow Nucleated Cells, CD22 Positive | Phase 1 / Phase 2 | Terminated | M.D. Anderson Cancer Center | 37 | 2018-08-24 | 2025-12-12 |
| Inotuzumab Ozogamicin in Treating Patients With Relapsed or Refractory CD22 Positive Acute Lymphoblastic Leukemia Inotuzumab Ozogamicin - CD22 Positive, Recurrent Acute Lymphoblastic Leukemia | Phase 2 | Terminated | M.D. Anderson Cancer Center | 4 | 2017-11-30 | 2021-04-12 |
| Phase I/II Study of Bosutinib in Combination With Inotuzumab Ozogamicin in CD22-positive PC Positive ALL and CML Bosutinib, Inotuzumab Ozogamicin - B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Phase 1 / Phase 2 | Completed | M.D. Anderson Cancer Center | 22 | 2015-04-16 | 2023-07-17 |
Burkitt Lymphoma (3) · Blast Crisis (1) · Disease Progression (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (1) · Lymphoma, Non-Hodgkin (1) · Neoplasm, Residual (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1)
Hemic and Lymphatic Diseases (5) · Neoplasms (5) · Neoplasms by Histologic Type (5) · Immune System Diseases (4) · Immunoproliferative Disorders (4) · Lymphatic Diseases (4) · Lymphoproliferative Disorders (4) · DNA Virus Infections (3) · Epstein-Barr Virus Infections (3) · Hematologic Diseases (3) · Herpesviridae Infections (3) · Infections (3) · Leukemia (3) · Lymphoma (3) · Lymphoma, B-Cell (3)
Inotuzumab Ozogamicin (3) · Cyclophosphamide (1) · Vincristine (1) · bosutinib (1) · fludarabine (1)
M.D. Anderson Cancer Center (4) · Roswell Park Cancer Institute (1)
United States (5)
Nitin Jain (2) · Elias Jabbour (1) · Eunice S Wang (1) · Jin S Im (1)
P30CA016672 (2)